EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic, Bioavailability, and Excretion Study of Cistanoside A Following Intragastric and Intravenous Administration in Rats Using Ultra‐High Performance Liquid Chromatography–Tandem Mass Spectrometry

Jingjing Sun, Yifan Gu, Chunyan Gu, Wenjie Gu, Jiawei Shen iD

Biomedical Chromatography · 2026-07 · 40 (7)

DOI: 10.1002/bmc.70508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 01.06.2026. Verfasst von Jingjing Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Wujing Community Health Service Center, Minhang District, Shanghai, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cistanoside A (Cis A) has received more attention because of its potential in the treatment of osteoporosis. However, its in vivo process remains unknown. In this study, a simple liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed and validated for the determination of cistanoside A in rat plasma, urine, and feces. After prepared by protein precipitation, cistanoside A and IS were separated on a Waters BEH C18 column with MS detection operated in positive multiple reaction monitoring mode. The method was fully validated and applied to the pharmacokinetic and excretion studies of cistanoside A in rats after intravenous (5 mg/kg) and oral (10, 20, and 40 mg/kg) administration. After intravenous administration, cistanoside A showed moderate clearance (0.52 ± 0.04 L*h/kg), low volume of distribution, and short terminal half‐life (0.43 ± 0.03 h). After oral administration at doses of 10, 20, and 40 mg/kg, the system exposure increased lower than the increase of dose, and the oral bioavailabilities were 0.39%, 0.38%, and 0.23%, respectively. After oral administration, the average cumulative excretion rate was 0.03% in urine and 1.62% in feces at 24 h. In summary, this study defined the pharmacokinetic and excretion characteristics of cistanoside A in rats, which could provide useful information for its further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryAnimalsRatsMaleReproducibility of ResultsRats, Sprague-DawleyChromatography, High Pressure LiquidBiological AvailabilityAdministration, OralLinear ModelsFecesLimit of DetectionAdministration, IntravenousSensitivity and Specificity

Stichwörter der Autor:innen

LC–MS/MSbioavailabilitycistanoside Aexcretionpharmacokinetics

Autor:innen und Institutionen

  • Department of Pharmacy, Wujing Community Health Service Center, Minhang District, Shanghai, China.
  • Department of Pharmacology, Shanghai Minhang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.

ORCID-Profile: Jiawei Shen

Zitieren

APA

Sun, J., Gu, Y., Gu, C., Gu, W., & Shen, J. (2026). Pharmacokinetic, Bioavailability, and Excretion Study of Cistanoside A Following Intragastric and Intravenous Administration in Rats Using Ultra‐High Performance Liquid Chromatography–Tandem Mass Spectrometry. Biomedical Chromatography, 40(7). https://doi.org/10.1002/bmc.70508

Vancouver

Sun J, Gu Y, Gu C, Gu W, Shen J. Pharmacokinetic, Bioavailability, and Excretion Study of Cistanoside A Following Intragastric and Intravenous Administration in Rats Using Ultra‐High Performance Liquid Chromatography–Tandem Mass Spectrometry. Biomedical Chromatography. 2026;40(7). doi:10.1002/bmc.70508

BibTeX
@article{Sun2026,
  author = {Sun, Jingjing and Gu, Yifan and Gu, Chunyan and Gu, Wenjie and Shen, Jiawei},
  title = {Pharmacokinetic, Bioavailability, and Excretion Study of Cistanoside A Following Intragastric and Intravenous Administration in Rats Using Ultra‐High Performance Liquid Chromatography–Tandem Mass Spectrometry},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {7},
  doi = {10.1002/bmc.70508}
}
Kostenlos starten →